163 related articles for article (PubMed ID: 18285440)
1. Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer.
Hughes MD
Stat Methods Med Res; 2008 Oct; 17(5):487-95. PubMed ID: 18285440
[TBL] [Abstract][Full Text] [Related]
2. Individual- and trial-level surrogacy in colorectal cancer.
Buyse M; Burzykowski T; Michiels S; Carroll K
Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
[TBL] [Abstract][Full Text] [Related]
3. Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective.
Piedbois P; Miller Croswell J
Stat Methods Med Res; 2008 Oct; 17(5):519-27. PubMed ID: 18285441
[TBL] [Abstract][Full Text] [Related]
4. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
5. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
Baker SG
Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
[TBL] [Abstract][Full Text] [Related]
6. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
Baker SG
Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
[TBL] [Abstract][Full Text] [Related]
7. Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues.
Chakravarty A; Sridhara R
Stat Methods Med Res; 2008 Oct; 17(5):515-8. PubMed ID: 18285437
[TBL] [Abstract][Full Text] [Related]
8. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
Buyse M
Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
[TBL] [Abstract][Full Text] [Related]
10. Surrogate endpoint validation: statistical elegance versus clinical relevance.
Green E; Yothers G; Sargent DJ
Stat Methods Med Res; 2008 Oct; 17(5):477-86. PubMed ID: 18285438
[TBL] [Abstract][Full Text] [Related]
11. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective.
Grothey A
Stat Methods Med Res; 2008 Oct; 17(5):529-35. PubMed ID: 18285442
[TBL] [Abstract][Full Text] [Related]
12. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.
Lassere MN
Stat Methods Med Res; 2008 Jun; 17(3):303-40. PubMed ID: 17925313
[TBL] [Abstract][Full Text] [Related]
13. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
14. Does the Prentice criterion validate surrogate endpoints?
Berger VW
Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
[TBL] [Abstract][Full Text] [Related]
15. Analysis of progression-free survival in oncology trials: some common statistical issues.
Carroll KJ
Pharm Stat; 2007; 6(2):99-113. PubMed ID: 17243095
[TBL] [Abstract][Full Text] [Related]
16. [Validation of surrogate endpoints in digestive oncology].
Methy N; Bedenne L; Bonnetain F
Bull Cancer; 2009 May; 96(5):591-5. PubMed ID: 19423485
[TBL] [Abstract][Full Text] [Related]
17. Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments.
Piedbois P; Buyse M
Curr Opin Oncol; 2008 Jul; 20(4):466-71. PubMed ID: 18525345
[TBL] [Abstract][Full Text] [Related]
18. Statistical evaluation of biomarkers as surrogate endpoints: a literature review.
Weir CJ; Walley RJ
Stat Med; 2006 Jan; 25(2):183-203. PubMed ID: 16252272
[TBL] [Abstract][Full Text] [Related]
19. Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: application to clinical trial data on chronic lymphocytic leukaemia.
Deslandes E; Chevret S
Stat Med; 2007 Dec; 26(30):5411-21. PubMed ID: 18058850
[TBL] [Abstract][Full Text] [Related]
20. Effects of cancer drugs on survival: often poorly evaluated.
Prescrire Int; 2009 Aug; 18(102):180-3. PubMed ID: 19746577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
